• PDS Biotechnology held its annual stockholder meeting on Aug. 10, 2026.
• Stockholders authorized an amendment doubling authorized common stock to 300,000,000 shares from 150,000,000; the charter was otherwise unchanged.
• Appointment of KPMG US LLP was ratified as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
• Two Class B directors, Kamil Ali-Jackson and Ilian Iliev, were elected to terms running to the 2029 annual meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-032947), on August 14, 2026, and is solely responsible for the information contained therein.